190 related articles for article (PubMed ID: 22672259)
1. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity.
Hoerster R; Muether P; Dahlke C; Mehler K; Oberthür A; Kirchhof B; Fauser S
Acta Ophthalmol; 2013 Feb; 91(1):e74-5. PubMed ID: 22672259
[No Abstract] [Full Text] [Related]
2. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M
JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183
[No Abstract] [Full Text] [Related]
3. Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies.
Park SW; Jung HH; Heo H
Acta Ophthalmol; 2014 Dec; 92(8):810-3. PubMed ID: 24909062
[No Abstract] [Full Text] [Related]
4. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.
Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD
J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243
[TBL] [Abstract][Full Text] [Related]
5. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity.
Castellanos MA; Schwartz S; García-Aguirre G; Quiroz-Mercado H
Br J Ophthalmol; 2013 Jul; 97(7):816-9. PubMed ID: 23221964
[TBL] [Abstract][Full Text] [Related]
6. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY.
Harper CA; Wright LM; Young RC; Read SP; Chang EY
Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248
[TBL] [Abstract][Full Text] [Related]
7. Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity.
Suk KK; Berrocal AM; Murray TG; Rich R; Major JC; Hess D; Johnson RA
J Pediatr Ophthalmol Strabismus; 2010 Dec; 47 Online():e1-4. PubMed ID: 21175113
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.
Menke MN; Framme C; Nelle M; Berger MR; Sturm V; Wolf S
BMC Ophthalmol; 2015 Mar; 15():20. PubMed ID: 25886603
[TBL] [Abstract][Full Text] [Related]
9. Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity.
Sahinoglu-Keskek N; Akkoyun I; Torer B
Eur J Ophthalmol; 2021 Jan; 31(1):179-183. PubMed ID: 31718282
[TBL] [Abstract][Full Text] [Related]
10. What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?
Spandau U
Acta Ophthalmol; 2013 Mar; 91(2):e154. PubMed ID: 22989079
[No Abstract] [Full Text] [Related]
11. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab.
Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC
Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab.
Zhou Y; Jiang Y; Bai Y; Wen J; Chen L
Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):31-6. PubMed ID: 25851862
[TBL] [Abstract][Full Text] [Related]
13. Dramatic regression of persistent tunica vasculosa lentis associated with retinopathy of prematurity following treatment with intravitreal bevacizumab.
Goldman DR; Baumal CR
J Pediatr Ophthalmol Strabismus; 2013 Jun; 50 Online():e27-9. PubMed ID: 24601434
[TBL] [Abstract][Full Text] [Related]
14. [The clinical study on intravitreous injection of ranibizumab for aggressive posterior retinopathy of prematurity].
Tian R; Zhang G; Tang S; Guo J; Tan W
Zhonghua Yan Ke Za Zhi; 2015 Nov; 51(11):822-5. PubMed ID: 26850583
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
[TBL] [Abstract][Full Text] [Related]
16. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up.
Martínez-Castellanos MA; Schwartz S; Hernández-Rojas ML; Kon-Jara VA; García-Aguirre G; Guerrero-Naranjo JL; Chan RV; Quiroz-Mercado H
Retina; 2013 Feb; 33(2):329-38. PubMed ID: 23099498
[TBL] [Abstract][Full Text] [Related]
17. Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.
Harder BC; von Baltz S; Schlichtenbrede FC; Jonas JB
Arch Ophthalmol; 2012 Jun; 130(6):800-1. PubMed ID: 22801850
[No Abstract] [Full Text] [Related]
18. Efficacy of ultra-low-dose (0.1 mg) ranibizumab intravitreal injection for treatment of prethreshold type 1 retinopathy of prematurity: A case series.
Ahmed IS; Hadi AM; Hassan HH
Eur J Ophthalmol; 2020 Jan; 30(1):40-47. PubMed ID: 30428702
[TBL] [Abstract][Full Text] [Related]
19. Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity.
Patel RD; Blair MP; Shapiro MJ; Lichtenstein SJ
Arch Ophthalmol; 2012 Jun; 130(6):801-2. PubMed ID: 22801851
[No Abstract] [Full Text] [Related]
20. Ultra-low dose of intravitreal bevacizumab in the treatment of retinopathy of prematurity.
Connor AJ; Papastavrou VT; Hillier RJ; Shafiq A
J Pediatr Ophthalmol Strabismus; 2015 Apr; 52 Online():e20-1. PubMed ID: 25942065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
